Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay

Desai, Neelam V.; Torous, Vanda; Parker, Joel; Auman, James T.; Rosson, Gary B.; Cruz, Cassandra; Perou, Charles M.; Schnitt, Stuart J.; Tung, Nadine

doi:10.1186/s13058-018-1005-z

Table 1 Clinical and pathologic characteristics of breast cancer patients with positive HER2 alternative probe

From: Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay

Patient no.	Histology	Grade	ER/PR	HER2 IHC^a	HER2 Copies	HER2/CEP17 ratio	HER2/P53 ratio	HER2 FISH repeated on a 2nd tumor specimen	Intrinsic subtype	TNM stage	Herceptin ± chemo given?	NAT, AT, MET	Herceptin ± chemo regimen^b	If NAT, pathologic response?	Follow-up time^c	Disease status
1	IDC	3	+/+	+ 2	4.15	1.1	2.2	Negative	Luminal A	pT1aN0	No	N/A	N/A	N/A	16 months	Remission
2	ILC	2	+/−	+ 2	4.47	1.5	2.9	Negative	Normal	cT2N1	No	NAT	ddAC-T	PR	42 months	Remission
3	IDC	3	+/+	+ 2	5.77	1.8	2.8	Not done	Luminal A	cT3N0	Yes	NAT	THP	CR	22 months	Remission
4^d	IDC	3	+/+	+ 2	4.9	1.2	2.8	Not done	Luminal B	cT1cN1	Yes	NAT	ddAC-THP	PR	16 months	Remission
5	IDC	2	+/+	0–1+	4.67	1.5	2.1	Pos by alt probe	Luminal A	pT1aN0	Yes	AT	TH	N/A	24 months	Remission
6^e	IDC	2	+/+	+ 3	4.51	1.3	2.6	Pos by alt probe	Luminal B	pT1bNx	Yes	AT	TCy-HP	N/A	15 months	Remission
7	IDLC	2	+/+	+ 2	4.88	1.5	3.0	Pos by conventional FISH^f	Luminal A	pT2N2	Yes	AT	ddAC-THP	N/A	12 months	Remission
8	IDLC	3	+/+	+ 2	4.05	1.9	2.2	Not done	Luminal A	pT1cN1a	Yes	AT	TCy-H	N/A	35 months	Remission
9	IDC	3	+/−	+ 2	4.62	1.5	2.7	Negative	Luminal B	cT1cN1a	Yes	AT	TCH	N/A	33 months	Remission
10	IDC	2	+/+	+ 2	5.42	1.5	2.6	Not done	Luminal A	cT2N1a	Yes	AT	ddAC-THP	N/A	31 months	Remission
11	IDLC	3	+/+	+ 3	5.42	1.3	2.6	Not done	Luminal B	cT2N0	Yes	AT	ddAC-THP	N/A	18 months	Remission
12	IDLC	2	+/+	+ 2	4.45	1.5	3.3	Negative	Luminal A	pT1bN0	Yes	AT	TH	N/A	29 months	Remission
13	IDC	2	+/+	+ 2	4.12	1.2	2.1	Negative	Luminal A	cT2N1M1b	Yes	MET	capecitabine	N/A	19 months	Stable dz
14	IDC	1	+/−	+ 3	5.93	1.7	2.8	na	Luminal A	na	na	na	na	na	na	na
15	IDC	3	−/−	0–1+	5.56	1.2	2.3	Negative	NS	cT2N0	Yes	NAT	ddAC-THP as NAT, capecitabine as AT	PR	27 months	Remission
16	IDC	2	+/+	+ 3	5.83	1.6	3.2	Not done	NS	pT1bN0	Yes	AT	TH	N/A	40 months	Remission
17	IDC	2	+/+	0–1+	4.17	1.3	2.3	Not done	NS	pT1cN1mi	No	AT	TCy	N/A	26 months	Remission
18	IDLC	2	+/+	+ 2	4.72	1.2	3.3	Not done	NS	pT1bN0	Yes	AT	trastuzumab and endocrine tx	N/A	2 months	Remission
19	ILC	2	+/+	+ 2	4.37	1.6	2.7	Not done	NS	cTxNxM1b	Yes	MET	Various chemo + anti-HER2 tx	N/A	36 months	Died of disease
20	ILC	2	+/+	+ 2	4.62	1.5	2.3	na	NS	na	na	na	na	na	na	na
21	IDLC	1	+/+	+ 2	4.42	1.4	2.6	na	NS	na	na	na	na	na	na	na
22	IDC	3	+/+	+ 2	4.42	1.6	2.2	na	NS	pT2N2Mx	na	na	na	na		na
23	IDC	1	+/+	+ 2	4.45	1.6	2.1	na	NS	na	na	na	na	na	na	na
24	IDLC	3	+/+	0–1+	4.13	1.5	2.9	Not done	NS	pT1cN0	na	na	na	na	na	na
25	IDLC	3	+/+	+ 2	4.68	1.2	2.5	na	NS	na	na	na	na	na	na	na
26^d	IDLC	2	+/+	0–1+	5.13	1.4	2.1	Not done	Luminal A	pT1cN0	No	N/A	N/A	N/A	9 months	Remission
27^d	IDLC	2	+/+	+ 2	4.22	1.7	3.2	Positive by conventional FISH^f	Luminal A	pT1bN0	Yes	AT	TH ×2 weeks, then T-DM1 ×3 doses	N/A	13 months	Remission
28	IDC	3	+/+	+ 2	5.17	1.9	2.2	Not done	Luminal A	pT1bN0	Yes	AT	TH	N/A	7 months	Remission
29	IDC	2	+/+	+ 2	4.79	1.4	2.5	Negative	Luminal A	pT2N1a	Yes	AT	ddAC-THP	N/A	6 months	Remission
30	IDC	2	+/+	+ 2	4.45	1.6	3.5	na	Luminal B	na	na	na	na	na	na	na
31	IDC	2	+/+	+ 3	5.07	1.3	2.6	na	Luminal A	na	na	na	na	na	na	na

^aHER2 IHC: 0–1+ is negative, 2+ is equivocal, 3+ is positive
^bAll patients who received trastuzumab-based treatment received trastuzumab (H) for 1 year unless otherwise specified
^cFollow up time defined as time in months from date of initial breast biopsy to date of last clinical follow-up
^dPatients with oncotype Dx score: patient 4 score 29, patient 26 score 12, patient 27 score 21
^ePatient had post-mastectomy recurrence and had history of prior ALND; so current nodal status could not be assessed
^fRepeat HER2 testing for patient 7 showed HER2 copies of 4.53 and HER2/CEP17 ratio of 2.0 and for patient 27 showed HER2 copies of 6.5 and HER2/CEP17 ratio of 2.3
AT adjuvant therapy, CR complete response, ddAC dose-dense adriamycin + cyclophosphamide, ER estrogen receptor, FISH fluorescence in-situ hybridization, H herceptin (trastuzumab), HER2 human epidermal growth factor receptor 2, IDC invasive ductal cancer, IDLC invasive cancer with ductal and lobular features, IHC immunohistochemistry, ILC invasive lobular cancer, MET therapy for metastatic disease, N/A not applicable, na not available, NAT neoadjuvant therapy, NS not sufficient for testing, P pertuzumab, PR partial response, PR progesterone receptor, T weekly paclitaxel ×12, TC taxotere (docetaxel) + carboplatin, TCy taxotere (docetaxel) + cyclophosphamide, TNM tumor node metastasis, Tx therapy

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us